CA2918242C — Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
Assigned to Merck Patent GmbH · Expires 2022-06-21 · 4y expired
What this patent protects
The present invention relates to pyridine, pyrimidine, and pyrazene compounds of Formula The present application further relates to pharmaceutically acceptable compositions comprising compounds of Fommla I. The compounds of Fonnula I, and the pharmaceutical compositions thereof, …
USPTO Abstract
The present invention relates to pyridine, pyrimidine, and pyrazene compounds of Formula The present application further relates to pharmaceutically acceptable compositions comprising compounds of Fommla I. The compounds of Fonnula I, and the pharmaceutical compositions thereof, are useful as BTK inhibitors.
Drugs covered by this patent
- Calquence (ACALABRUTINIB) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.